[Future challenges and prospects for drug companies].
The challenge for drug companies is to work with healthcare professionals and public-sector stakeholders in order to ensure therapeutic progress and better healthcare. Faced with major scientific and economic upheavals, the industry's model of innovation is being totally revisited. France has always been an important home for the drugs industry. Indeed, this country has numerous advantages (human resources, top-flight research, production tools, etc.) and a vibrant professional pharmaceutical syndicate. Yet France is falling further and further behind in the international race. Competition no longer takes place solely between economic players, but now also between geographic zones. Will companies operating in France be able to meet the challenges of collaborative public-private research and changes in the means of production, the two key levers for future success? The main priority now is to ensure coherence between national healthcare policy and industrial policy, if France is to become a world leader in the life sciences and healthcare. Only efficient cooperation between the authorities, stakeholders and companies, will enable us to achieve this goal.
Lajoux
Christian
C
Entreprises du Médicament (LEEM), 88, rue de la Faisanderie 75782 Paris.
D004345:Drug Industry / Q000639:trends*; D005544:Forecasting; D005602:France